Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Radiation Therapy with or without Apalutamide in Treating Patients with Stage III-IV Prostate Cancer

This phase II trial studies how well radiation therapy with or without apalutamide works in treating patients with stage III-IV prostate cancer. Radiation therapy uses high energy x-ray to kill tumor cells and shrink tumors. Androgen can cause the growth of prostate cancer cells. Drugs, such as apalutamide, may lessen the amount of androgen made by the body. Giving radiation therapy and apalutamide may work better at treating prostate cancer.
Not Available
II
Kirschner, Austin
NCT03371719
NRGUROGU006

Panitumumab, Nivolumab, and Ipilimumab in Treating Patients with KRAS, NRAS, or BRAF Wild-Type MSS Refractory Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

This phase II trial studies how well panitumumab, nivolumab, and ipilimumab work in treating patients with KRAS, NRAS, or BRAF wild-type microsatellite stable (MSS) colorectal cancer that does not respond to treatment, has spread to other places in the body, and cannot be removed by surgery. Monoclonal antibodies, such as panitumumab, nivolumab, and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
Not Available
II
Ciombor, Kristen
NCT03442569
VICCGI18116

Safety and Efficacy of Tipifarnib in Head and Neck Cancer With HRAS Mutations and Impact of HRAS on Response to Therapy

An international, multicenter, open-label, 2 cohort, non-comparative, pivotal study evaluating the efficacy of tipifarnib in HRAS mutant HNSCC (AIM-HN). The first cohort will assess the objective response rate (ORR) of tipifarnib in subjects with HNSCC with HRAS mutations. The second study cohort, SEQ-HN, is an observational sub-study and includes 2 types of patients: (1) the historical record of first line therapy in subjects with HRAS mutant HNSCC participating in Cohort 1 in whom first line outcome data are available and (2) matched control HNSCC patients in whom HRAS mutations were not identified (wild type HRAS HNSCC) and who consent to provide first line outcome data and additional follow up.
Not Available
II
Gibson, Mike
NCT03719690
VICCHN18117

Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer

This is an international, multi-center, open-label, phase II study in patients with metastatic urothelial cancer after failure of platinum-based regimen or anti-PD-1 / PD-L1 based immunotherapy. At least 140 patients are anticipated to be enrolled across approximately 70 sites from North America, Europe and Asia.
Not Available
II
Davis, Nancy
NCT03547973
VICCURO18120

Efficacy and Safety of KD025 in Subjects With cGVHD After At Least 2 Prior Lines of Systemic Therapy

This is a Phase 2, randomized, multicenter study to evaluate the efficacy and safety of KD025 in subjects with Chronic Graft Versus Host Disease (cGVHD) after at least 2 prior lines of systemic therapy
Not Available
II
Jagasia, Madan
NCT03640481
VICCBMT18121


Nashville Biosciences Blood Sample Collection Study

Not Available
N/A
Bernard, Gordon
VICCMD18123

Long Term Follow-up for Early Detection of Lung Cancer in Current or Former Smokers

Lung

This research trial studies the long term follow-up for early detection of lung cancer in current or former smokers. Following up on smokers by collecting and analyzing specimens in the laboratory, performing chest computed tomography (CT) scans, as well as reviewing medical records may help doctors detect lung cancer at an earlier stage.
Lung
N/A
Massion, Pierre
NCT03181256
VICCTHO1730

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients with Newly Diagnosed WNT-Driven Medulloblastoma

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT) / Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.
Not Available
II
Pastakia, Devang
NCT02724579
COGACNS1422

Olaparib in Treating Patients with Advanced Glioma, Cholangiocarcinoma, or Solid Tumors with IDH1 or IDH2 Mutations

This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that have spread to other places in the body and usually cannot be cured or controlled with treatment. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Not Available
II
Davis, Elizabeth
NCT03212274
VICCMD18129

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: